Articles related to ABORTION

A large-scale randomized controlled trial (n=1,504) demonstrates that medication abortion initiated before ultrasound confirmation of intrauterine pregnancy achieves a 95.2% complete abortion rate, statistically noninferior to standard delayed treatment protocols.

The recent study underscores the readiness of pharmacists to dispense mifepristone following the FDA’s rule change. With basic training, nearly all participants expressed confidence in their ability to dispense this medication, highlighting your adaptability and resourcefulness.

With a growing debate around the British Journal of Psychiatry’s decision not to retract a controversial abortion paper, we invite you to delve deeper into the ensuing implications for scientific publication standards and the interplay between science, politics, and law.

The modified Mifepristone Risk Evaluation and Mitigation Strategy (REMS) Program eliminates the requirement for in-person dispensing and replaces it with a requirement that pharmacies dispense the drug be certified. Mifepristone, a progestin antagonist, may now be dispensed by or under the supervision of a certified prescriber, or by a certified pharmacy on a prescription issued by a certified prescriber, for medical termination of pregnancy up to 10 weeks gestation (70 days or less since the first day of the last menstrual period).

Publication: JAMAMethod: Electronic health record (EHR) data from 8 health systems over seven 4-week surveillance periods to identify and assign gestational ages for spontaneous abortions and ongoing pregnancies; analyzed and compared odds of receiving a COVID-19 vaccine in the 28 days prior to spontaneous abortion and ongoing pregnancies.Results: Of 105,446 unique pregnancies, 13,160 spontaneous abortions and 92,286 ongoing pregnancies were identified; spontaneous abortions did not have an increased odds of exposure to a COVID-19 vaccination in the prior 28 days compared with ongoing pregnancies.